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Abstract [First level heading] 
Drug-induced liver injury (DILI) is a potentially fatal adverse event with significant medical 
and economic impact. Many drugs, especially anti-infective, neurologic or pain-modifying 
substances, act as hepatotoxins. With cardiovascular toxicity, liver toxicity is one of the two 
leading causes for drug withdrawal from the market. The liver can be affected directly, in a 
predictable and dose-dependent manner, or idiosyncratically, independent of the dose and 
therefore unpredictable. 
 
Currently DILI is a diagnosis of exclusion that physicians have to bear in mind in patients 
with an unexplained increase of liver enzymes. The type of injury is categorized into 
hepatocellular, cholestatic, or mixed by the respective enzyme pattern of injury. Symptoms of 
affected patients can mimic any other liver disease.  
 
Therefore, new diagnostic and prognostic biomarkers for early liver injury are currently being 
evaluated in multi-centre clinical trials that are conducted by international consortia and other 
initiatives. Pharmacogenetic testing, next-generation sequencing, proteomics, metabolomics 
and mechanistic markers can help to preselect susceptible patient populations and tailor drug 
therapy to individual patients. Proposed DILI indicators which are under investigation include 
microRNAs, cytokeratin-18, high mobility group box protein 1, and several other biomarkers. 
These developments can change clinical practice, and improve patients’ safety and 
management. However, they have not been translated into clinical practice or approved for 
routine use yet. Management of DILI usually consists of initial withdrawal of the suspected 
drug and—if applicable—administration of specific antidotes, such as N-acetylcysteine. 
However, the overall management of DILI could change in the near future with the advent of 
novel diagnostic and prognostic DILI markers.  
Introduction [First level heading] 
Drug-induced liver injury (DILI) is a potentially fatal adverse event. It is the most frequent 
cause of acute liver failure when acetaminophen overdose is included and is therefore 
medically relevant, exhibiting a high morbidity and mortality [1]. It is also of economic 
importance and represents the second most frequent cause for drug withdrawal from the 
pharmaceutical market. 
 
Many agents, for example, anti-infectives, neurologic, cholesterol-lowering or pain-modifying 
substances, can act as hepatotoxins [2] (Table 1). They can either damage the liver directly in 
a dose-dependent and therefore predictable fashion, or idiosyncratically by immunologic 
mechanisms or metabolic activation independent of the dose. The latter is unpredictable, but 
unfortunately the more common event, if serious liver injury caused by 
acetaminophen/paracetamol (APAP) overdose is not accounted for. Symptoms of affected 
patients are non-specific and include nausea, discomfort in the right upper abdominal 
quadrant, dark urine, or fatigue. 
[INSERT TABLE 1 HERE] 
To substantiate the relationship between an administered drug and liver injury, other causes of 
acute hepatocellular injury need to be excluded. These comprise viral hepatitis (HAV, HBV, 
HCV, HEV, EBV, CMV), ischemic liver injury, autoimmune hepatitis, Budd-Chiari 
syndrome, Wilson’s disease and, in cases of cholestatic liver injury, other causes of 
extrahepatic or intrahepatic cholestasis, such as choledocholithiasis, malignancy, primary 
biliary cirrhosis, or sclerosing cholangitis. After exclusion of these differential diagnoses, 
physicians have to consider DILI in patients with an unexplained increase in liver enzymes [3 
4]. Currently DILI is categorized into hepatocellular (R-value [ALT/ULN ÷ ALP/ULN] ≥5), 
cholestatic (R-value ≤2), or mixed-type injury (R-value 2-5) by the respective enzyme pattern 
in blood (Table 1). The temporal relation to the administration of a potential hepatotoxin and 
the exclusion of other differential causes are the cornerstones for establishing a diagnosis of 
DILI. For causality assessment, different tools such as the RUCAM or Maria and Victorino 
score are available [5–7]. 
 
However, new diagnostic biomarkers for liver injury are currently under investigation in 
various mechanistic and pre-clinical models and also in large clinical trials.  
 
Diagnosing DILI: future biomarkers [First level heading] 
Several consortia are dedicated to evaluating new biomarkers in the diagnosis and 
management of DILI. Although the objectives of the various endeavours differ, the translation 
of preclinical mechanism-based findings into clinical liver safety assessment offers a unique 
opportunity to move the field forward.  
 
The US Drug-Induced Liver Injury Network (DILIN) recruits patients with idiosyncratic DILI 
in both retrospective and prospective study registries. The international Drug-Induced Liver 
Injury Consortium (iDILIC) is a multinational scientific group coordinated by the University 
of Newcastle and University of Nottingham [8]. Genetic associations with DILI are 
investigated in different centres in Europe and the US. Predicting DILI by genetic risk factors 
and identifying potential hepatotoxins before they lead to severe liver injury are the primary 
goals of investigation. For this purpose, DNA isolated from patients with DILI is analysed, for 
example, in genome-wide association studies (GWAS) [9]. Genetic associations have been 
shown for flucloxacillin-induced DILI and the HLA-B*5701 allele [10 11]. With this 
predisposition, an 80-fold increase in the risk of developing DILI was attributed, resulting in 
an absolute risk of 1:500–1:1000. Pharmacogenetic testing of HLA-B*5701 is mandatory in 
patients scheduled to receive abacavir to prevent hypersensitivity [12 13]. Donaldson and co-
workers [14] identified human leukocyte antigen (HLA) class II genotypes in association with 
amoxicillin/clavulanate associated DILI. For lumiracoxib, a cyclooxygenase-2 (COX-2) 
selective inhibitor, HLA-DR and HLA-DQ genotypes were found to be predictive for DILI 
[15 16]. This drug was withdrawn from the market because of hepatotoxicity. Lapatinib, a 
tyrosine kinase inhibitor, has been associated with DILI in carriers of the HLA allele 
DQA*02:01 [17 18]. An association between DILI caused by ximelagatran, a direct thrombin 
inhibitor, and HLA-DRB1*0701 and HLA-DQA1*02 was reported [19]. In the case of 
alanine aminotransferase (ALT) elevations caused by ximelagatran, colony-stimulating factor 
1 receptor (CSF1R), the receptor for the respective cytokine, was increased significantly in 
plasma [20], leading to a new quest for early identification tools. 
 
The SAFE-T Consortium (Safer and Faster Evidence-based Translation) is focused on the 
identification of new biomarkers for DILI [21]. Funded by the Innovative Medicines Initiative 
(IMI) the consortium aims to identify new tools to predict, detect and monitor drug-induced 
organ toxicity in a more specific, sensitive and predictive manner. Academic centres, 
pharmaceutical companies and small- to medium-sized enterprises collaborate to promote a 
personalized medicine approach in the prediction and management of DILI. Toxicities to 
other organs of interest are analysed in drug-induced kidney injury (DIKI) and drug-induced 
vascular injury (DIVI) work packages. Another IMI project, called MIP-DILI (Mechanism-
Based Integrated Systems for the Prediction of Drug-Induced Liver Injury), focuses on the 
development of preclinical test systems that integrate multiple preclinical data types to 
improve prediction of DILI in man. 
 
The PSTC (Predictive Safety Testing Consortium) was created by the Critical Path Institute 
and aims to qualify new biomarkers for the detection and monitoring of drug-induced toxicity 
in preclinical and clinical studies [22 23]. In this respect, PSTC is the preclinical counterpart 
of the SAFE-T consortium, since both aim to qualify biomarkers that allow the separation of 
patients with a self-limiting course of DILI from those that progress to severe DILI and 
ultimately liver failure. This prognostic assessment is currently performed by use of Hy’s law 
that predicts a 10% risk of fatality in cases in which a 3-fold elevation of ALT above the 
upper limit of normal (ULN) is accompanied by a 2-fold elevation of bilirubin [24 25]. The 
elevation of bilirubin in these cases is the sequel of progressive hepatocellular death. For the 
rapid identification of potential cases of Hy’s law, the FDA introduced the eDISH program 
(evaluation of Drug-Induced Serious Hepatotoxicity) in 2004, which has since been 
implemented to assess DILI in clinical trials [26].  
 
New biomarkers should improve patient safety and also reduce drug attrition due to toxicity. 
Further investigated and proposed markers for DILI include liver injury markers such as 
microRNAs (miRNA), mechanistic biomarkers such as high mobility group box protein 1 
(HMGB-1) and Cytokeratin-18 fragments, and metabolites from urine and serum [27]. 
Circulating serum miRNAs such as miR-122 and miR-192 are liver-specific [28 29] and are 
proposed as potentially sensitive and specific markers of liver injury [27]. With a short half-
life they are released into plasma in acute and chronic liver injury [30]. HMGB-1 is a 
molecular pattern protein marking necrosis: in the acetylated form it indicates immune 
activation [31]. Cytokeratin-18 (CK18) and miRNA-122 were evaluated as superior 
biomarkers compared to ALT in terms of sensitivity and specificity in DILI [32]. CK18 
together with HMGB-1 point towards the mechanism of hepatocellular death in APAP 
overdose, notably the degree of necrosis vs. apoptosis [31 33]. The performance of 
combinations of biomarkers is likely to surpass that of a single biomarker alone, depending on 
the context of its use. Thus, the balance between apoptosis and necrosis may be indicative of 
the subsequent course the patient will follow, given that the liver is unique in its ability to 
activate defence mechanisms against toxic injury. 
 
Idiosyncratic DILI is usually detected in a late stage of drug development—often after drug 
approval in phase IV studies or pharmacovigilance surveillance. An understanding of the 
pathophysiologic processes in this type of hepatotoxicity is of special interest to both 
pharmaceutical companies and regulatory authorities. In cases of APAP hepatotoxicity, levels 
of mitochondrial and nuclear DNA could differentiate patients who developed acute liver 
failure, but subsequently recovered, from those who died [34]. These mechanistic markers 
could provide further insight into the pathophysiological mechanisms of DILI, allowing early 
detection and outcome prediction. In vitro generated hepatocytes derived from skin biopsies 
of patients with an idiosyncratic reaction could be used to study the unique features of the 
affected individuals’ hepatocytes, as well as the genotype-phenotype correlation in DILI [35]. 
These new techniques and models hold great promise to improve drug safety—with back-
translation from bedside to bench.  
 
Management and outlook [First level heading] 
Until now, the management of DILI has usually consisted of initial withdrawal of the 
suspected drug. Targeted therapy with antidotes, such as N-acetylcysteine in paracetamol 
(acetaminophen) overdose, is possible in defined cases. Re-challenge with the causative agent 
can lead to an augmented adverse effect, especially in immunologically mediated DILI, and is 
therefore not recommended. Preventive or prophylactic measures against DILI include 
patients’ education and alerting health care professionals towards liver enzyme monitoring 
under therapy with a potentially hepatotoxic drug. Pharmacogenetic tests, including next-
generation sequencing, proteomic or metabolomic approaches for preselecting susceptible 
patient populations, and tailoring drug therapy to individual patients, have not yet been 
approved for routine clinical practice. To what extent these new markers will change clinical 
practice for the prevention of DILI remains to be seen. Ongoing efforts aim to overcome the 
gap between bench and bedside towards the early detection of DILI and the identification of 
patients at risk. Important results from major consortia such as DILIN, SAFE-T, MIP-DILI, 
PSTC and iDILIC can be expected in 2015. 
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Tables 
Table 1: Liver injury patterns and examples of hepatotoxic drugs  
Type of liver injury Hepatocellular Mixed Cholestatic 
 Injury predominantly to 
hepatocytes 
Hepatocellular and cholestatic 
injury 
Injury to bile ducts or affecting 
bile flow 
R-Value ≥5 >2 and <5 ≤2 
 [𝑅 =
𝐴𝐿𝑇/𝑈𝐿𝑁_𝐴𝐿𝑇
𝐴𝐿𝑃/𝑈𝐿𝐿_𝐴𝐿𝑃
]    
Examples 
Drug Classes 
   
Antiinfectives Ciprofloxacin, isoniazid, 
rifampicin, tetracyclines, 
ketoconazole 
Amoxicillin/clavulanic acid, 
clindamycin, erythromycin, 
nitrofurantoin, sulfonamides, 
cotrimoxazole 
Amoxicillin/clavulanic acid, 
erythromycin 
Pain medication Paracetamol (Acetaminophen), 
Aspirin, NSAIDs 
  
Hormones  Anabolic steroids Anabolic steroids, estrogen, oral 
contraceptives 
Cardiovascular and metabolic 
drugs 
Lisinopril, losartan, statins, 
allopurinol 
Enalapril, verapamil Clopidogrel, irbesartan 
Neurologic/Psychiatric drugs Valproic acid Carbamazepine, phenytoin Chlorpromazine, tricyclic 
antidepressants 
 
ALT, alanine aminotransferase; ALP, alkaline phosphatase; R, ratio; ULN, upper limit normal. 
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